TRVX - Abstract: ASCO20 Virtual Scientific Program, May 29-31
Phase I/II study to evaluate systemic durvalumab + intraperitoneal (IP) ONCOS-102 in patients with peritoneal disease who have epithelial ovarian (OC) or metastatic colorectal cancer (CRC): Interim phase I clinical and translational results.
Session: Developmental Therapeutics—Immunotherapy
Author(s): Dmitriy Zamarin, Kunle Odunsi, Brian M. Slomovitz, Linda R. Duska, John J. Nemunaitis, Matthew Reilley, Yonina Bykov, Aliya Holland, Vanessa M. Hubbard-Lucey, Lisa Shohara, Paul Schwarzenberger, Toni Ricciardi, Mary J. Macri, Aileen Ryan, Magnus E. Jaderberg, Ralph R. Venhaus
Abstract: 3017
Poster: 81
Redigert 21.01.2021 kl 00:11
Du må logge inn for å svare
heilo888
29.04.2020 kl 21:39
1259
Nå har vel Trvx steget så mye at den begynner å bli overmoden for nok en emisjon.
Redigert 21.01.2021 kl 00:11
Du må logge inn for å svare
HP17
29.04.2020 kl 21:40
1255
Det er et godt poeng.
Redigert 21.01.2021 kl 00:11
Du må logge inn for å svare